Screener
Immunovant, Inc. IMVT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Accounts payable | $7,541 | $17,656 |
| Accrued expenses | 96,634 | 50,748 |
| Current portion of operating lease liabilities | 72 | 98 |
| Due to Roivant Sciences Ltd. | 175 | 273 |
| Total current liabilities | 104,422 | 68,775 |
| Total liabilities | 104,422 | 68,775 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s accrued expenses?
- Immunovant, Inc. (IMVT) reported accrued expenses of $175K in Q1 2026.
- How has Immunovant, Inc.'s accrued expenses changed year-over-year?
- Immunovant, Inc.'s accrued expenses decreased by 35.9% year-over-year, from $273K to $175K.
- What is the long-term trend for Immunovant, Inc.'s accrued expenses?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s accrued expenses has grown at a -59.0% compound annual growth rate (CAGR), from $15.16M to $175K.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Immunovant, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude